In the following tables, revenues are disaggregated by category, sales by geographic market and sales by product data. The following breaks down revenues into the following categories (in thousands):

	Years Ended
	2018		2017		2016
Non-consignment sales	$	106,338	$	74,163	$	65,037
Consignment sales		17,616		16,448		17,395
Total net sales		123,954		90,611		82,432

Note 16 — Disaggregation of Revenues, Geographic Sales and Product Sales (Continued)

The Company markets and sells its products in more than 75 countries and conducts its manufacturing in the United States. Other than China, Japan and the United States, the Company does not conduct business in any country in which its sales in that country exceed 10% of consolidated net sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers was as follows (in thousands):

	Years Ended
	2018		2017		2016
China⁽¹⁾	$	46,070	$	24,473	$	16,624
Japan		23,151		18,125		17,327
United States		7,316		7,894		9,859
Other⁽²⁾		47,417		40,119		38,622
Total net sales	$	123,954	$	90,611	$	82,432

⁽¹⁾	Starting in fiscal 2018, the China region includes sales into China and Hong Kong. Sales for fiscal 2017 and 2016, also reflect sales into Hong Kong so as to be comparable to 2018 presentation, where previously Hong Kong sales were included in the other line item.

⁽²⁾	No other location individually exceeds 10% of the total net sales.

	Years Ended
	2018		2017		2016
Domestic	$	7,316	$	7,894	$	9,859
Foreign		116,638		82,717		72,573
Total net sales	$	123,954	$	90,611	$	82,432

100% of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes the operating decisions and allocates resources based upon the consolidated operating results, therefore, the Company operates as one operating segment for financial reporting purposes. The Company’s principal products are IOLs used in cataract surgery and ICLs used in refractive surgery. The composition of the Company’s net sales by product line was as follows (in thousands):

	Years Ended
	2018		2017		2016
ICLs	$	101,082	$	68,325	$	59,111
Other product sales
IOLs		16,193		17,258		19,706
Other surgical products		6,679		5,028		3,615
Total other product sales		22,872		22,286		23,321
Total net sales	$	123,954	$	90,611	$	82,432

Note 16 — Disaggregation of Revenues, Geographic Sales and Product Sales (Continued)

The composition of the Company’s long-lived assets, consisting of property and equipment, net, and intangible assets, net, between those in the United States, Switzerland, and Japan is set forth below as of December 28, 2018 and December 29, 2017 (in thousands):

	2018		2017
U.S.	$	10,416	$	8,523
Switzerland		705		912
Japan		573		612
Total	$	11,694	$	10,047

The Company sells its products internationally, which subjects the Company to several potential risks, including fluctuating exchange rates (to the extent the Company’s transactions are not in U.S. dollars), regulation of fund transfers by foreign governments, United States and foreign export and import duties and tariffs, and political instability.